Artiva halts AlloNK after FDA trial pause

 

cuts 94% of staff and hires Leerink Partners for strategic review

• One AlloNK trial death was attributed to fludarabine-associated neurotoxicity, according to Artiva Biotherapeutics.
• Two patient deaths prompted the FDA to pause the Phase 2 AlloNK trial, leading Artiva to halt development.
• The company cited safety and durability concerns as factors in discontinuing development of its lead AlloNK (AB-101) program.
• Strategic review may include a sale, merger, asset transaction or liquidation of Artiva Biotherapeutics or its programs.
• Artiva reported preliminary cash, cash equivalents and investments of about $319.1 million as of Sept. 30, 2026.

https://finviz.com/stock?t=ARTV&p=d